Haven Capital Group Inc. Makes New Investment in Incyte Co. (NASDAQ:INCY)

Haven Capital Group Inc. purchased a new stake in Incyte Co. (NASDAQ:INCY) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 20,142 shares of the biopharmaceutical company’s stock, valued at approximately $1,391,000. Incyte comprises 1.3% of Haven Capital Group Inc.’s portfolio, making the stock its 20th biggest position.

Other institutional investors have also made changes to their positions in the company. Quintet Private Bank Europe S.A. bought a new stake in shares of Incyte in the 4th quarter valued at approximately $26,000. Global X Japan Co. Ltd. increased its holdings in shares of Incyte by 144.7% in the 4th quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 230 shares during the last quarter. R Squared Ltd bought a new stake in shares of Incyte in the 4th quarter valued at approximately $30,000. Brooklyn Investment Group bought a new stake in shares of Incyte in the 3rd quarter valued at approximately $30,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Incyte in the 3rd quarter valued at approximately $33,000. 96.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. William Blair reiterated an “outperform” rating on shares of Incyte in a report on Friday, December 13th. Stifel Nicolaus boosted their price objective on Incyte from $75.00 to $77.00 and gave the company a “hold” rating in a research report on Monday, February 10th. Royal Bank of Canada reduced their price objective on Incyte from $70.00 to $68.00 and set a “sector perform” rating for the company in a research report on Tuesday, February 11th. JMP Securities restated a “market perform” rating on shares of Incyte in a research report on Tuesday, February 11th. Finally, StockNews.com lowered Incyte from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $75.25.

Incyte Stock Down 8.6 %

INCY opened at $62.01 on Tuesday. Incyte Co. has a one year low of $50.35 and a one year high of $83.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.94 and a current ratio of 1.97. The stock’s fifty day moving average is $71.55 and its 200-day moving average is $70.31. The company has a market capitalization of $12.00 billion, a PE ratio of 229.68, a P/E/G ratio of 0.41 and a beta of 0.76.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. On average, equities analysts predict that Incyte Co. will post 4.86 EPS for the current fiscal year.

Insider Transactions at Incyte

In other news, EVP Sheila A. Denton sold 14,069 shares of the business’s stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $74.07, for a total value of $1,042,090.83. Following the sale, the executive vice president now owns 25,848 shares of the company’s stock, valued at approximately $1,914,561.36. The trade was a 35.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Steven H. Stein sold 12,352 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $72.69, for a total value of $897,866.88. Following the sale, the executive vice president now directly owns 66,967 shares in the company, valued at $4,867,831.23. This trade represents a 15.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,020 shares of company stock valued at $1,981,882. Corporate insiders own 17.60% of the company’s stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.